Futuristics
Long/short equity, biotech, healthcare, small-cap

Niraparib And Rolapitant Will Take Tesaro To New Heights

Waltham, Massachusetts, based Tesaro (NASDAQ:TSRO), is an oncology-focused biopharma company, which develops and commercializes effective therapeutics for cancer patients. The company aims to leverage its experience to identify, acquire, and develop promising drug candidates as well as commercialize them for the treatment of cancer patients. It in-licenses these products rather than perform in-house drug discovery. TSRO has seen a growth of more than 100% since the beginning of this year.

TSRO data by YCharts

The second-half of 2013 will be more important from investors' perspective, as I expect Tesaro's first Phase 3 data readout, that includes Rolapitant data for prevention of chemotherapy induced nausea and vomiting, or CINV. With Niraparib gaining more visibility as PARP inhibitor for...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details